Edecesertib

DB18917InvestigationalSmall molecule

Edecesertib is under investigation in clinical trial NCT05629208 (Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)).

Chemical structure of Edecesertib
Formula / weight
C22H22FN7O2 · 435.463 g/mol (avg)
Also known as
3-Pyridinecarboxamide, 4-[[(1R)-1-cyanoethyl]amino]-6-(3-cyanopyrrolo[1,2-b]pyridazin-7-yl)-N-[(2R)-2-fluoro-3-hydroxy-3-methylbutyl]- · 4-{[(1R)-1-cyanoethyl]amino}-6-(3-cyanopyrrolo[1,2- b]pyridazin-7-yl)-N-[(2R)-2-fluoro-3-hydroxy-3- methylbutyl]pyridine-3-carboxamide
Code names
GS-5718

Resolves to

Compound
UNII3NUJ7N1277CAS2408839-73-4
Structure
InChIKeyHORBHQPSWJRDSV-ZUOKHONESA-NSMILESC[C@@H](NC1=CC(=NC=C1C(=O)NC[C@@H](F)C(C)(C)O)C1=CC=C2C=C(C=NN12)C#N)C#N
Targets
Q9NWZ3IRAK4

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Edecesertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In